uniQure (NASDAQ:QURE) Trading Up 5.8% on Analyst Upgrade

uniQure (NASDAQ:QURE) shares were up 5.8% during mid-day trading on Friday after Mizuho raised their price target on the stock from $7.00 to $20.00. Mizuho currently has a neutral rating on the stock. uniQure traded as high as $16.38 and last traded at $16.36. Approximately 193,269 shares were traded during trading, a decline of 88% from the average daily volume of 1,651,960 shares. The stock had previously closed at $15.47.

Several other research analysts have also issued reports on QURE. Leerink Partners raised their target price on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. StockNews.com raised uniQure to a “sell” rating in a research note on Wednesday, December 11th. Finally, Cantor Fitzgerald lifted their price target on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.88.

Insider Buying and Selling at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. RTW Investments LP acquired a new stake in uniQure in the 3rd quarter valued at approximately $49,000. China Universal Asset Management Co. Ltd. grew its stake in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares in the last quarter. Atria Investments Inc acquired a new stake in shares of uniQure in the third quarter valued at approximately $53,000. Quarry LP acquired a new position in uniQure during the third quarter valued at approximately $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its stake in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Trading Up 9.8 %

The company has a market cap of $827.66 million, a P/E ratio of -3.42 and a beta of 0.89. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business has a 50 day moving average price of $8.13 and a 200-day moving average price of $6.76.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. Analysts forecast that uniQure will post -3.82 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.